Funding
← Back to your selection

TCGX

Activity from announced rounds

All recorded activity
Rounds participated in
5
Confirmed lead rounds
—
5 roles undisclosed
New companies
5
First participation on record · 0 follow-on
Funding in participating rounds
$982M
5 disclosed · full round size, not this investor’s share

By stage

Series B3
Series A1
Series C+1

By primary sector

Biotech5

By country

United States3
Denmark1
Switzerland1

Rounds

5 in all activity
Vaderis Therapeutics

Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia

$152MSeries B
Role not disclosed
Ollin Biosciences

Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD

$330MSeries B
Role not disclosed
Adcendo

Adcendo develops antibody-drug conjugates that deliver cancer drugs to tumor-associated targets, with clinical programs in solid tumors and soft tissue sarcoma.

$75MSeries C
Role not disclosed
Mirador Therapeutics

Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases

$250MSeries B
Role not disclosed